ABIVAX Société Anonyme (ABVX)
The price, the headline numbers and the latest news, in one place.
ABIVAX Société Anonyme (ABVX) Stock Price, Analysis & Data
| Bid | 121.16 |
| Market Cap | 9.75B |
| Revenue (ttm) | 4.92M |
| Net Income (ttm) | -332M |
| -0.23 | |
| -5.34 | |
| n/a | |
| -35.52 | |
| P/B (ttm) | 17.70 |
| P/S (ttm) | 1981.48 |
| Earnings Date | Sep 21, 2026 |
| Ask | 119.33 |
| Volume | 1,056,674 |
| Avg. Volume (20D) | 1,906,019 |
| Open | 112.17 |
| Previous Close | 113.35 |
| Day's Range | 111.36 - 114.33 |
| 52-Week Range | 69.81 - 148.83 |
| Analyst | n/a |
| Price Target | 170 (52.15%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in...
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -336.1M, an increase of 90.7%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for ABVX stock is "null". The 12-month stock price forecast is 170, which is upside of 52.15% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.71 exceeds estimates by 0.10, with 25.26% YoY growth.
Analysts project revenue of ... Upgrade
